From the President and CEO's email I just got today, on 8.20.22
"Dear Friends,"
"I have been telling you that our study started and right now we have 3 open sites. However, we will open about 40 sites in the US and here is the list of most of the sites that have agreed to participate. We are also opening sites in Europe, but that will be later in the year."
"As they open, the sites will also be listed in Clinicaltrials.gov search for Posiphen."
Best
Maria
Maria Maccecchini, PhD
President & CEO
Annovis Bio, Inc.
1055 Westlakes Drive
Berwyn, PA 19312
Written by
PDWarrior1900
To view profiles and participate in discussions please or .
MORE on my post above from the Annovisbio.com website:
"Buntanetap (previously known as ANVS401 or Posiphen) is our lead compound. It is a translational inhibitor of neurotoxic aggregating proteins (TINAPs). Different from monoclonal antibody therapies, buntanetap is an orally available small molecule, and its unique mechanism of action allows it to inhibit multiple neurotoxic proteins at once."
"Recent research has shown that multiple neurotoxic proteins are at play in all neurodegenerative diseases. Buntanetap, thus, offers a transformative and superior mechanism to treat neurodegenerative disorders. It’s being developed for Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions such as Alzheimer’s in Down syndrome."
"Buntanetap is our lead compound. It is in clinical trials for PD and AD. In preclinical studies it improved axonal transport in these diseases by inhibiting the neurotoxic proteins that kill nerve cells. It was shown in human and animal studies to lower APP/Aβ, tau/phospho-tau, and α-synuclein, the neurotoxic proteins that impair axonal transport and lead to inflammation and cell death."
"The compound was tested in three Phase 1 and two Phase 2 clinical studies that show it is well tolerated. In the two Phase 2 clinical studies buntanetap showed efficacy in AD and PD patients."
"Buntanetap-treated PD patients showed statistically significant improvements in both the speed and the accuracy of execution in the WAIS Coding Scale and MDS-UPDRS test. Buntanetap-treated AD patients showed a statistically significant cognitive improvement of 30% as measured by ADAS-Cog11 and in the WAIS Coding Scale, when compared with baseline results. Buntanetap is the only drug so far to show improvement in cognition in AD patients and motor function in PD patients."
Interesting! Thanks for sharing….it could help with both PD and AD which is interesting. It looks like the early stage PD trial starts first then the late stage.
they've already completed successful clinical trials for stage 1 and stage 2... stage 3 clinical trials are starting NOW! I just got another email from their president/CEO with an excel list of the 40 USA cities that you can volunteer to participate in that trial...-------------------
i'm waiting now for her reply for my request for a 'link' to that list of 40 USA cities so I can post it here
I took Posiphen in an early clinical trial in early 2020 but didn’t know what the results were regarding any benefit. Hope it comes to fruition and really helps.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease
Designer DNA drug therapy for Parkinson's disease trial initiation expected in 2023
MAO-B inhibitors, natural sources, how they effect GABA, and neuroprotective potential 
